Etouillie was great and his experience commentary made the course more interesting. His biosimilar section is highly pertinent to the US current situation with lawsuits flying every which way. I do wish more regulatory process steps were included. The start up success last section was not helpful. More just seemed like a quick review article one could read about an approved drug and the story of someone bragging about how lucky they were.

The course was very interesting and cover differents topics to give me an overview of drug commercialization in USA. In addition, the experiences shared from the each professor was excelent. However, I didn't know that the majority of topics were made in 2013. So this information was missing when I applied for this course.

I found this course to be very engaging and informative about the Drug Development Process. However, most of the information is outdated - the course was recorded in 2015 and a lot has changed in pharma since then. I would give it a 5-stare rating if I had taken the course say 4-5 years ago.

It is an excellent course from Coursera for learning on strategies for drug commercialization including pharmacoeconomics and how pharmaceuticals partners with other stakeholders to accomplish this.

Most of materials are quite outdated and also quality of presentations sometimes was not that good.

Not enough materials on HEOR and Phase IV studies. Week 4's lectures were redundant.

Its a wonderful course, but i would request the faculty to include more recent data

some lectures are not understand

but generally

thank you

The managed markets data was old, needs to be updated.

It was alright, couldve given more examples and cases

i think part one in week 4 is too bad

Audio ruim

goodsir

So so

good

ok

Outdated series of classes that offer no real learning opportunities.

The course needs to be updated with much newer lectures.

The sound quality in a lot of the lectures was quite bad.